Group 1 - The article highlights a series of corruption cases involving pharmaceutical companies and agents bribing hospital personnel, with the National Healthcare Security Administration (NHSA) stating that such bribery disrupts normal medical practices and shifts sales from clinical value to high rebates and kickbacks [2][6] - Multiple companies, including Medtronic and A-share listed companies like Qianhong Pharmaceutical and Dezhan Health, have been named in recent court rulings related to these corruption cases [2][5] - Specific cases include Medtronic's agents bribing hospital officials with kickbacks of 5,000 yuan per stent and varying amounts for balloons, leading to a total bribe exceeding 14 million yuan [3][4] Group 2 - The case involving Qianhong Pharmaceutical and Dezhan Health reveals that from January 2013 to May 2019, a hospital's pharmacy director received over 116,000 yuan in bribes from various pharmaceutical representatives, including 4,100 yuan from Qianhong Pharmaceutical [5] - The NHSA has established a credit evaluation system for pricing and procurement to address the inflated prices revealed by these cases, aiming to protect patients and healthcare funds [6]

Core Insights - The National Healthcare Security Administration (NHSA) has recently exposed multiple corruption and illegal cases involving various pharmaceutical companies, including Medtronic, Qianhong Pharmaceutical, and Dezhan Health, highlighting systemic issues in the medical procurement process [1][4]. Group 1: Corruption Cases - Medtronic's agents were found to have bribed hospital officials to promote the sale of stents and balloons, with kickbacks of 5,000 RMB per stent and varying amounts for balloons based on their price [2][3]. - The total amount of bribes received by a hospital vice president from Medtronic's agents was reported to be over 6.74 million RMB from 2014 to 2018 [2]. - In a separate case, Qianhong Pharmaceutical and Dezhan Health were implicated in bribery involving hospital procurement officials, with Qianhong's agent providing 41,000 RMB in kickbacks [4]. Group 2: Regulatory Response - The NHSA has established a credit evaluation system for pricing and procurement to address the issues of inflated drug prices and corruption, aiming to protect patients and healthcare funds [5]. - The NHSA plans to guide local healthcare authorities in implementing trust ratings for companies involved in bribery and misconduct, enforcing measures to ensure compliance and safeguard healthcare funds [5].